Brian Flowers, MD
Ophthalmology · Fort Worth, TXNPI 1902802242
Payments from drug & device makers
Across 447 payments — averaging $630.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$87K
- Alcon$82K
- Alcon Research LLC$77K
- Ivantis, Inc$28K
- Sight Sciences, Inc.$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- plus $4K from 22 others
Across 204 payments — averaging $3988.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$489K
- NEW World Medical,inc.$123K
- Ivantis, Inc$112K
- Sight Sciences, Inc.$74K
- Alcon Research LLC$15K
What the payments were for
- Consulting fees$113,88973%
- Speaking & faculty fees$2,5002%
- Grants$25,00016%
- Travel & lodging$2,8902%
- Food & beverage$11,4657%
- Gifts$1000%
- Entertainment$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 144 | $87,254 |
| Alcon | 107 | $82,364 |
| Alcon Research LLC | 25 | $76,954 |
| Ivantis, Inc | 9 | $27,578 |
| Sight Sciences, Inc. | 14 | $1,986 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $1,935 |
| AbbVie(2 entities) | 51 | $1,550 |
| Aerie Pharmaceuticals, Inc. | 23 | $559 |
| NEW World Medical,inc. | 7 | $371 |
| Johnson & Johnson Surgical Vision, Inc. | 12 | $262 |
| Bausch & Lomb Americas Inc. | 9 | $204 |
| Thea Pharma Inc. | 9 | $185 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $97 |
| Rxsight Inc | 3 | $90 |
| Carl Zeiss Meditec USA, Inc. | 2 | $87 |
| Sun Pharmaceutical Industries Inc. | 4 | $81 |
| Mallinckrodt Hospital Products Inc. | 1 | $76 |
| Stryker | 1 | $71 |
| ANI Pharmaceuticals, Inc. | 2 | $57 |
| Optos, Inc. | 1 | $47 |
| Ocular Therapeutix, Inc. | 2 | $45 |
| Nova Eye, Inc. | 1 | $44 |
| Coopervision Inc. | 1 | $25 |
| W. L. Gore & Associates, Inc. | 1 | $25 |
| Biotissue Holdings Inc. | 1 | $19 |
| Zimmer Biomet | 1 | $16 |
| Oyster Point Pharma, Inc. | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$85,411
- Voyager DSLT$28,674
- iStent inject W$2,750
- iDose TR$1,760
- VYZULTA$1,720
- OMNI(R) SURGICAL SYSTEM (US)$1,605
- iStent Trabecular Micro-Bypass Stent System$1,600
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$1,400
- PRESERFLO MicroShunt$1,295
- iDose$800
- Travoprost Intraocular Implant - iDose$800
- DURYSTA$250
- Rocklatan$184
- Rhopressa$184
- iDoseTR$168
- iStent Trabecular Micro-Bypass System Model iS3$142
How this compares
$282,005 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 204 | $86,350 |
| RhopressaNetarsudil Mesylate | 151 | $68,832 |
| RocklatanNetarsudil Mesylat/Latanoprost | 92 | $49,035 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 159 | $46,496 |
| Prednisolone Acetate | 635 | $32,487 |
| Latanoprost | 3,248 | $31,162 |
| CombiganBrimonidine Tartrate/Timolol | 79 | $29,240 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 166 | $23,766 |
| XiidraLifitegrast | 13 | $18,164 |
| Brinzolamide | 104 | $16,447 |
| Timolol Maleate | 1,506 | $15,790 |
| RestasisCyclosporine | 12 | $13,607 |
| Alphagan PBrimonidine Tartrate | 33 | $13,594 |
| VyzultaLatanoprostene Bunod | 14 | $8,975 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 666 | $8,810 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $1,550 | $142,792328 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $559 | $117,867243 claims |
| AlconSimbrinza | $82,364 | $46,496159 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $204 | $27,14027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Fort Worth
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Patrick WilliamsArlington$6.6M
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
- Michael SingerSan Antonio$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.